22:51 , Aug 9, 2019 |  BC Extra  |  Company News

BridgeBio looks to fully own its CV subsidiary Eidos

BridgeBio fell $2.94 (10%) to $26.88 Friday after proposing Thursday to fully acquire its cardiovascular-focused subsidiary Eidos, which climbed $3.11 (10%) to $35.17 on the news. BridgeBio Pharma Inc. (NASDAQ:BBIO), which has a 66.6% stake...
20:01 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Eidos starts Phase III of AG10 in TTR amyloid cardiomyopathy

Eidos Therapeutics Inc. (NASDAQ:EIDX) began the two-part Phase III ATTRibute-CM trial evaluating AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy. The primary endpoint for the first part of the trial is the change from baseline in...
17:28 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Eidos' AG10 leads to >90% TTR stabilization at day 28 in Phase II

Eidos Therapeutics Inc. (NASDAQ:EIDX) said AG10 led to >90% stabilization of transthyretin (TTR) at day 28 in all treated patients in a Phase II trial to treat symptomatic TTR amyloid cardiomyopathy. Twice-daily AG10 significantly increased...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
22:28 , Aug 27, 2018 |  BC Extra  |  Clinical News

Pfizer eyes submission after TTR readout; Alnylam gets bump

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality. However, investors...
19:20 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Eidos raises $106M in IPO priced at top of range

Eidos Therapeutics Inc. (NASDAQ:EIDX) added $6.12 (36%) to $23.12 June 20 after raising $106.3 million through the sale of 6.3 million shares at $17 in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and...
14:15 , Jun 20, 2018 |  BC Extra  |  Financial News

Eidos gets first-day bump after pricing IPO at top of range

Eidos Therapeutics Inc. (NASDAQ:EIDX) added $6.12 (36%) to $23.12 Wednesday after raising $106.3 million through the sale of 6.3 million shares at $17 in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays....
19:16 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Eidos proposes $115M NASDAQ IPO

Eidos Therapeutics Inc. (Palo Alto, Calif.) proposed on May 25 to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. In April, the company raised $64 million in a...
22:08 , May 25, 2018 |  BC Extra  |  Financial News

Eidos, Avrobio propose NASDAQ IPOs

Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday. Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. Last...
17:06 , Apr 6, 2018 |  BC Week In Review  |  Financial News

RA Capital leads Eidos' $64M series B round

Eidos Therapeutics Inc. (San Francisco, Calif.) raised a $64 million series B round led by new investor RA Capital. Eidos' parent company, BridgeBio Pharma LLC (Palo Alto, Calif.), also participated, as did new investors Janus...